cyc 202 has been researched along with palbociclib in 15 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (palbociclib) | Trials (palbociclib) | Recent Studies (post-2010) (palbociclib) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 911 | 126 | 864 |
| Protein | Taxonomy | cyc 202 (IC50) | palbociclib (IC50) |
|---|---|---|---|
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Cyclin-T1 | Homo sapiens (human) | 1.5085 | |
| Cyclin-K | Homo sapiens (human) | 1.207 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 9.8 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0109 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 9.8 | |
| Cyclin-A2 | Homo sapiens (human) | 2.2042 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.021 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0115 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 9.15 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 4.1887 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.0127 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0194 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 3.48 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.1821 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.0631 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Akula, B; Athuluridivakar, S; Baker, SJ; Bharathi, EV; Billa, VK; Cosenza, SC; Mallireddigari, MR; Padgaonkar, A; Pallela, VR; Reddy, EP; Reddy, MV; Subbaiah, DR; Vasquez-Del Carpio, R | 1 |
| Havlíček, L; Jorda, R; Kryštof, V; Pospíšil, T; Skrášková, Z; Strnad, M; Šturc, A; Vymětalová, L | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Joshi, G; Kalra, S; Kumar, R; Munshi, A | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Marzaro, G; Poratti, M | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Chen, K; Jiang, H; Li, J; Li, Y; Lin, T; Liu, L; Luo, C; Xu, P; Zhou, B | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y | 1 |
| Graña, X; Knudsen, ES; Mayhew, CN; Reed, CA; Rivadeneira, DB; Sotillo, E; Thangavel, C | 1 |
| Fernandez-Espinosa, DD; Isaja, L; Marazita, MC; Morris-Hanon, O; Romorini, L; Scassa, ME; Sevlever, GE; Videla-Richardson, GA | 1 |
4 review(s) available for cyc 202 and palbociclib
| Article | Year |
|---|---|
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Topics: Amino Acid Sequence; Animals; Computer-Aided Design; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Design; Humans; Models, Molecular; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Sequence Alignment | 2017 |
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
Topics: Aminopyridines; Benzimidazoles; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Humans; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Structure-Activity Relationship | 2019 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2022 |
11 other study(ies) available for cyc 202 and palbociclib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Drug Screening Assays, Antitumor; Female; Heterografts; Humans; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasm Transplantation; Protein Kinases; Pyridines; Pyrimidines; Repressor Proteins; Structure-Activity Relationship | 2014 |
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; G2 Phase; Humans; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2016 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Structure-Activity Relationship | 2021 |
Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
Topics: Adenovirus E1A Proteins; Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Disease Models, Animal; E2F Transcription Factors; Gene Knockdown Techniques; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Male; Mice; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retinoblastoma Protein; Retinoblastoma-Like Protein p107; RNA Interference; Roscovitine; Time Factors; Transfection | 2010 |
Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
Topics: Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Fibroblasts; Glioma; Humans; Neoplastic Stem Cells; Phenotype; Piperazines; Pyridines; Roscovitine | 2019 |